Business Wire11.12.19
Sensydia Corporation, an innovator in rapid, non-invasive measurement of critical cardiac function, has appointed Anthony Arnold as CEO and president and joins the Board of Directors. Arnold is a pioneer in bioelectronic medicine and surgical navigation and brings more than 20 years of leadership experience from a range of medical technology companies including Smith+Nephew plc, Medtronic plc, Boston Scientific Corp., and SetPoint Medical.
“Anthony’s appointment comes at an exciting time for Sensydia, as the company builds on its lead product, the FDA-approved Cardiac Performance System (CPS), to strengthen and expand its technical capabilities and clinical applications,” said Aman Mahajan, M.D., Ph.D., founder and chief medical officer of Sensydia. “Anthony’s expertise and leadership in the medtech field will help position Sensydia and advance its innovative technology to commercialization.”
“We’ve been investors in Sensydia from day one, and we are beyond thrilled to have an industry leader of Anthony’s stature leading Sensydia,” said Victoria Grace, founding partner of Colle Capital. “Anthony’s enthusiasm for Sensydia’s technology and approach only strengthens our original thesis for the company’s potential. We firmly believe this is a solution to cardiac care that could change and improve quality of care not only at the clinical level, but one that could act as a preventive tool at the consumer level.”
“Sensydia has breakthrough technology that provides rapid, non-invasive monitoring of ejection fraction and other critical cardiac function, backed up with stellar research and technology development capabilities,” said Arnold. “Sensydia’s mission is to provide fast, easy-to-use, non-invasive monitoring of key cardiac performance metrics to reduce re-admissions, lower the cost of care and improve outcomes for patients with heart disease.”
Arnold’s experience leading medtech companies includes his most recent role as president and CEO of SetPoint Medical, a clinical-stage company developing bioelectronic therapy for chronic inflammatory diseases, where he helped create the field of bioelectronic medicine and raised $75 million in venture funding from strategic and venture sources to build SetPoint into one of the most promising companies in the space. Prior to SetPoint, he held leadership roles of increasing responsibility with Smith+Nephew, Medtronic and Boston Scientific, with a focus on building and motivating groundbreaking medtech teams to deliver paradigm-shifting products.
Sensydia is committed to developing technology for the non-invasive diagnosis and management of patients with heart disease. Sensydia merged expertise in clinical cardiology, biomedical engineering and machine learning in the development of fast, wireless cardiac function monitoring. The company’s lead product, cleared by the U.S. Food and Drug Administration for ejection fraction in 2018, is the Cardiac Performance System (CPS), a non-invasive, patient-worn device for automated measurement of ejection fraction, proven in clinical trials to be similar in accuracy to echocardiography.
“Anthony’s appointment comes at an exciting time for Sensydia, as the company builds on its lead product, the FDA-approved Cardiac Performance System (CPS), to strengthen and expand its technical capabilities and clinical applications,” said Aman Mahajan, M.D., Ph.D., founder and chief medical officer of Sensydia. “Anthony’s expertise and leadership in the medtech field will help position Sensydia and advance its innovative technology to commercialization.”
“We’ve been investors in Sensydia from day one, and we are beyond thrilled to have an industry leader of Anthony’s stature leading Sensydia,” said Victoria Grace, founding partner of Colle Capital. “Anthony’s enthusiasm for Sensydia’s technology and approach only strengthens our original thesis for the company’s potential. We firmly believe this is a solution to cardiac care that could change and improve quality of care not only at the clinical level, but one that could act as a preventive tool at the consumer level.”
“Sensydia has breakthrough technology that provides rapid, non-invasive monitoring of ejection fraction and other critical cardiac function, backed up with stellar research and technology development capabilities,” said Arnold. “Sensydia’s mission is to provide fast, easy-to-use, non-invasive monitoring of key cardiac performance metrics to reduce re-admissions, lower the cost of care and improve outcomes for patients with heart disease.”
Arnold’s experience leading medtech companies includes his most recent role as president and CEO of SetPoint Medical, a clinical-stage company developing bioelectronic therapy for chronic inflammatory diseases, where he helped create the field of bioelectronic medicine and raised $75 million in venture funding from strategic and venture sources to build SetPoint into one of the most promising companies in the space. Prior to SetPoint, he held leadership roles of increasing responsibility with Smith+Nephew, Medtronic and Boston Scientific, with a focus on building and motivating groundbreaking medtech teams to deliver paradigm-shifting products.
Sensydia is committed to developing technology for the non-invasive diagnosis and management of patients with heart disease. Sensydia merged expertise in clinical cardiology, biomedical engineering and machine learning in the development of fast, wireless cardiac function monitoring. The company’s lead product, cleared by the U.S. Food and Drug Administration for ejection fraction in 2018, is the Cardiac Performance System (CPS), a non-invasive, patient-worn device for automated measurement of ejection fraction, proven in clinical trials to be similar in accuracy to echocardiography.
